Eli Lilly’s Tirzepatide Becomes World’s Top-Selling Drug
Eli Lilly’s tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, has overtaken Merck’s cancer therapy Keytruda to become the world’s best-selling medicine, reflecting surging global demand for GLP-1-based weight loss treatments. Record-Breaking Sales Eli Lilly reported third-quarter 2025 sales of $10.1 billion for tirzepatide, surpassing the $8.1 billion in sales posted by Merck’s […]
Continue Reading